Movmedix exhibits at the AOSSM 2026 annual meeting
Advancing orthopedic surgery and sports medicine through innovation and clinical collaboration
The 2026 Annual Meeting of the American Orthopaedic Society for Sports Medicine (AOSSM) marked an important milestone for Movmedix. For the first time, we exhibited at one of the leading sports medicine congresses in the United States, taking another significant step in our international development.
Our first step into the U.S. market
Our participation follows the recent 510(k) FDA clearance of the LARS® ACJ solution for Acromioclavicular (AC) joint injuries. This achievement has enabled Movmedix to officially introduce its technology to the U.S. market and bring with us more than 30 years legacy of expertise and French innovation in synthetic solutions.
Engaging with the U.S. sports medicine community
Throughout the congress, our team had the opportunity to meet orthopedic surgeons, sports medicine specialists, distributors, and industry partners. These valuable discussions allowed us to present the LARS® portfolio, exchange clinical perspectives, and gain deeper insights into the needs and expectations of the U.S. market.
Looking ahead
About Movmedix
Driven by our vision to restore infinite mobility to patients suffering from soft tissue injuries, Movmedix continues to evolve toward becoming a global leader in sports medicine. With more than three decades of expertise, we have been at the forefront of the artificial ligament field — pioneering free-fibre technology and designing implants tailored to specific clinical indications.
Building on the strong legacy of our LARS® (Ligament Advanced Reinforcement System) product range, we remain committed to developing innovative and disruptive solutions that address the evolving needs of surgeons and improve patient outcomes worldwide.
